EDNRA and pulmonary arterial hypertension: Marchant D et al.38 has proved that Bosentan, used for pulmonary arterial hypertension, could enhance viral load and MC severity through ETRA-mediated p38 MAPK activation and p38 MAPK is a desirable antiviral target in MC.